PUBLICATIONS RÉCENTES
Briot K, Roux C, Thomas T, Blain H, Buchon D, Chapurlat R, Debiais F, Feron JM, Gauvain JB, Guggenbuhl P, Legrand E, Lehr-Drylewicz AM, Lespessailles E, Tremollieres F, Weryha G, Cortet B. 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine. 2018 Apr 11. [Epub ahead of print]
Briot K, Roux C. Adult hypophosphatasia. Arch Pediatr. 2017 May;24(5S2):5S71-5S73
Roux C, Briot K. Osteoporosis in 2017: Addressing the crisis in the treatment of osteoporosis. Nat Rev Rheumatol. 2018 Feb;14(2):67-68
PMID: 29323345
Similar articles
Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. Osteoporos Int. 2017 Dec;28(12):3301-3314
Roux C, Baron G, Briot K, Roux B, Cortet B, Thomas T. Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study. Osteoporos Int. 2017 Dec;28(12):3339-3345.
Briot K. Sequential osteoporosis treatments. Joint Bone Spine. 2011; 78:545-9.
Briot K, Tubianna M, Bastit L, Muresan Kloos I, Roux C. Effects of switching aromatase inhibitors on arthralgia: the ATOLL study. Breast Cancer Research and Treatment 2010; 20: 127-34
Briot K, Legrand E, Pouchain D, Monnier S, Roux C. Accuracy of patient-reported height loss and risk factors for height loss among postmenopausal women. CMAJ 2010; 182: 558-62.
Briot K, Benhamou CL, Roux C. Increase in vertebral body size in postmenopausal women with osteoporosis. Bone 2010; 47:229-34.
Briot K, Kolta S, Flandre P, Boue F, Ngovan P, Cohen-Codar I, Emery Salbert F, Chauvin JP, Norton M, Delfraissy JF, Roux C. Bone mineral density changes in HIV-infected patients starting standard antiretroviral therapy or monotherapy. Bone 2011; 8: 1133-9.
Briot K, Ravaud P, Liu-Leage S, Roux C. Persistence with teriparatide in postmenopausal osteoporosis; impact of an education and follow-up program: the French experience. Osteoporos Int 2009; 20: 625-30.
Briot K, Roux C, Gossec L, Charni N, Kolta S, Dougados M, Garnero P. Effects of etanercept on serum biochemical markers of type II cartilage metabolism in patients with spondylarthropathy. J Rheumatol 2008; 35: 310-14.
Briot K, Gossec L, Kolta S, Dougados M, Roux C. Prospective assessment of body composition and bone density changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor (alpha) treatment. J Rheumatol 2008; 35: 855-61.
